UPDATED: Clovis buys EOS for $200m after 2-year interest in lucitanib
This article was originally published in Scrip
Executive Summary
Clovis Oncology's surging stock price gave the company the value it needed to acquire EOS for $10m in cash and $190m in Clovis common shares, and to access the private Italian firm's cancer drug lucitanib, which Boulder, Colorado-based Clovis has been tracking for two years.
You may also be interested in...
Finance Watch: 5AM, Longevity Close Funds, New Incubators Launch To Support Early-Stage Companies
News of 5AM's two latest venture funds follows the launch of Longevity Vision Fund as well as LA BioMed's and RUNLABS’ announcements that they will open new incubators in 2019. Also, Passage Bio launches with $115.5m, but the largest recent VC deal was HaiHe's $146.6m financing.
Finance Watch: Ten IPOs So Far In 2024, But Returns To Date Are Subpar
Public Company Edition: This year’s newly public companies are trading an average of 9.7% below their IPO prices, including the two most recent debuts, Boundless Bio and Contineum. Also, Nkarta, Praxis and Nurix grossed $240m, $200m and $175m, respectively, in follow-on offerings.
Venture Capital Fundraising Rebounds In Q1 As Mega-Rounds Dominate
Biopharma firms raised $6bn in the first quarter of 2024, the most of any quarter since Q2 2022. But without an increase in the number of companies raising funds, the rebound remains uneven.